Trial reportHaematologica2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Erratum issuedOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.Haematologica · 2026Article
- [Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
32 authors at 20 institutions in 3 countries.
Emilio IannittoLa Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palemo, Italy; Tumor Immunology Unit Department of Health Sciences University of Palermo School of Medicine. Istituto di Patologia Generale, Palermo.
Simone FerreroDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
Côme BommierUniversitè Paris Citè; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
Daniela DrandiDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
Martina FerranteDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
Krimo BouabdallahCHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire, Pessac.
Sylvain CarrasUniv. Grenoble Alpes. Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309). University Hospital, Molecular Biology and Hematology departments, Grenoble.
Guido GiniEmatologia AOU delle Marche, Ancona.
Vincent CamusDepartment of Hematology, Centre Henri Becquerel, Rouen.
Salvatrice MancusoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo.
Luigi MarcheselliFondazione Italiana Linfomi ETS, Modena.
Angela FerrariAzienda Unità Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia.
Michele MerliHematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese.
Benoit TessoulinNantes University Hospital and CRC2 NA, Nantes.
Caterina StelitanoUO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria.
Kheira BeldjordUniversitè Paris Citè.
Giovanni RotiDipartimento di Medicina e Chirurgia, Università di Parma, AOU di Parma.
Fabrice JardinEmatologia AOU delle Marche, Ancona.
Barbara CastagnariDepartment of Hematology, Ravenna hospital, Ravenna.
Francesca PalombiHematology Unit, IRCCS Regina Elena National Cancer Institute, Roma.
Lucile BaseggioLaboratoire d'Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon.
Alexandra Traverse-GlehenService d'Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon.
Claudio TripodoTumor Immunology Unit Department of Health Sciences University of Palermo School of Medicine. Istituto di Patologia Generale, Palermo.
Anna Marina LiberatiOncohematology Unit, University of Perugia, Azienda Ospedaliera S.Maria, Terni.
Margherita ParoliniEmatologia Istituto Romagnolo Per Lo studio dei Tumori Dino Amadori, Meldola.
Sara UsaiOspedale Oncologico A. Businco, Cagliari.
Caterina PattiU.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo.
Massimo FedericoCHIMOMO dept. University of Modena and Reggio Emilia.
Maurizio MussoLa Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palemo.
Marco LadettoUniversity of Eastern Piedmont Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria.
Emanuele ZuccaIOSI, Oncology Institute of Southern Switzerland and IOR: Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona, Switzerland.
Catherine ThieblemontUniversitè Paris Citè; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
Sorbonne Paris Cité · FRUniversity of Turin · ITHospices Civils de Lyon · FRLa Maddalena · ITMarche Polytechnic University · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera S.Maria · ITCentre Henri BecquerelCentre Hospitalier Universitaire de Bordeaux · FRFondazione Intergruppo Italiano Linfomi Onlus · ITInternational Extranodal Lymphoma Study Group · CHIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale di Circolo e Fondazione Macchi · ITOspedale Santa Maria · ITOspedale "Santa Maria delle Croci" di Ravenna · ITOspedale Vincenzo Cervello · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversité Grenoble Alpes · FRUniversity of Modena and Reggio Emilia · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideLymphoma, B-Cell, Marginal ZoneNeoplasm, ResidualRituximabSplenic NeoplasmsAgedFemaleHumansMaleMiddle AgedTreatment OutcomeBendamustine HydrochlorideRituximab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.